Medical/Pharmaceuticals
Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial
NANJING, China, Aug. 25, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data.This milestone endows...
2025-08-25 18:27
1765
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment ofFrancis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and ...
2025-08-25 16:42
1641
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
* The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 * DEEs ar...
2025-08-25 15:43
1225
Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts
EAST RUTHERFORD, N.J., Aug. 25, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility inWaltham, Massachusetts to fur...
2025-08-25 12:01
1527
Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform
* The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression level...
2025-08-22 18:14
2554
MALAYSIA SHOWCASES HEALTHCARE EXCELLENCE IN CAMBODIA, DRIVING MOMENTUM TOWARDS MYMT 2026
KUALA LUMPUR, Malaysia, Aug. 22, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC) proudly presents Malaysia Healthcare Week 2025 inPhnom Penh, Cambodia, an initiative designed to strengthening healthcare ties between the two nations and positionMalaysia as the medical tourism de...
2025-08-22 11:00
2817
Biosyngen Unveils Innovative Strategies for Next-Generation TIL Therapies in Asia Bio 2025 Singapore
SINGAPORE, Aug. 22, 2025 /PRNewswire/ -- Asia Bio Innovation Summit 2025 is one of the premier industry-focused events inAsia and focus on the hottest topics of ADC and CGT. Asia Bio Innovation summit 2025 Singapore brought together 30+ world-class Speakers, 10+ Exhibitors and 200+ Attendees from...
2025-08-22 09:55
2953
Doceree launches Premium Programmatic adding more context, more reach, and more formats to traditional HCP programmatic
* With Premium Programmatic, pharma marketers can now engage physicians across 2,000+ integrated specialist medical platforms delivering clinically aligned content at scale with unmatched precision and exclusive formats. SHORT HILLS, N.J., Aug. 21, 2025 /PRNewswire/ -- Doceree, the only AI-powe...
2025-08-21 21:32
2235
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. JENA, Germany, Aug. 21, 2025 /PRNewswire/ -- ZEISS Medical Technology today announced CE mark approval forCIRRUS® PathFinder™, an in...
2025-08-21 20:00
2799
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: Eng...
2025-08-21 18:02
3278
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM
Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solution...
2025-08-21 17:38
1674
Debut of new form of health supplement product! WCC biomedical collaborate with Synmosa toward the niche market!
TAIPEI, Aug. 21, 2025 /PRNewswire/ -- WCC Biomedical
2025-08-21 09:23
1591
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended30 June 2025. All figures are in USD unless stated otherwise. H1 2025 key results[1] Group performan...
2025-08-21 08:23
2628
Vital Materials Released Quantum Flux Photon Counting CT (PCCT) Full Vertical Integration Technology
BEIJING, Aug. 20, 2025 /PRNewswire/ -- From August 15-17, the 31st China International Medical Equipment Exhibition and Scientific Conference (China-Hospeq 2025) was held inBeijing. Vital Materials officially launched the VITA Genesis,China's fully proprietary Photon Counting CT (PCCT) scanner, ...
2025-08-20 10:45
1769
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 20, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based o...
2025-08-20 08:00
2652
ARC Therapies Advances Gut Microbiome Research with YB328 Toward Clinical Application
Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy TOKYO, Aug. 20, 2025 /PRNewswire/ -- ARC Therapies Inc. (Head Office: Shinjuku,Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research ofYB328, a newly identified ...
2025-08-20 07:00
1855
LabConnect Launches LabConnector™ to Streamline Lab Data Integration
New service ensures faster, more accurate data delivery to clients JOHNSON CITY, Tenn., Aug. 19, 2025 /PRNewswire/ -- LabConnect, LLC, a global leader in central laboratory services for clinical trials, today announced the launch of LabConnector™, a powerful new technology solution that transform...
2025-08-19 21:15
1415
Nature Medicine Publishes Results of Phase II Study of Sacituzumab Tirumotecan Plus Tagitanlimab as First-Line Therapy for NSCLC
CHENGDU, China, Aug. 19, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monocl...
2025-08-19 20:09
1644
Nilesh Shah joins Illumina as Head of Region, AMEA
SINGAPORE, Aug. 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global
leader in DNA sequencing and array-based technologies, announced today the
appointment ofNilesh Shah as Head of Region, AMEA, effective immediately.
2025-08-19 14:14
1940
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...
2025-08-19 13:26
1759
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 292 media titles]
2026-01-05 12:14
Novo Nordisk International Operations Commits to Veeva Vault CRM
[Picked up by 289 media titles]
2026-01-08 09:05Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Courtyard by Marriott Phuket, Patong Beach Resort: The Ultimate Family-Friendly Destination in 2026
[Picked up by 283 media titles]
2026-01-08 12:01
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 282 media titles]
2026-01-07 10:00
Most Read
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
8053
The Greatest Meeting The Greatest: Roborock joins hands with Real Madrid in strategic partnership with innovation at the core
2026-01-02 19:00
7540
